Hosted on MSN11mon
MannKind rises as FDA advances rare lung disease therapy to Phase 3 trial
investigational new drug application for MNKD-101, enabling the initiation of a Phase 3 study. This single registrational study, identified as ICoN-1, is likely to commence in the U.S. by the end ...